New

Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now

You have successfully sign out
Loading...
Shape
Zura Bio Limited
ZURA
Shape
US Flag

NASDAQ

Unprofitable

Unprofitable

302M

Biotechnology

Next Earning date - 11 Nov 2024

302M

Biotechnology

Next Earning date - 11 Nov 2024

4.74USD
Shape0.14 ( 3.04%)
favorite-chart

Relative Strenght

89
favorite-chart

Volume Buzz

14%
favorite-chart

Earning Acce

No
favorite-chart

Dist 52w H.

25%
OverviewChart

Quote Panel

Shape
Updated October 28, 2024
1W -3.66 % 1M 16.75 % 3M 17.91 % 1Y -3.46 %

Key Metrics

Shape

  • Market Cap

    302.29M

  • Shares Outstanding

    63.77M

  • Share in Float

    42.24M

  • Dividende

    0

  • Earning Date

    11 Nov 2024

  • Price Target

    4.74

  • Average Volume

    431312

  • Beta

    0.153

  • Range

    2.0-6.35

  • Industry

    Biotechnology

  • Website

    https://zurabio.com

  • Sector

    Healthcare

Fundamentals

Shape

N/A

P/E Ratio

0.00x

P/S Ratio

2.27x

P/B Ratio

0.0

Debt/Equity

0.0%

Net Margin

$0.6

EPS

How ZURA compares to sector?

P/E Ratio

ZURA

-12x

Relative Strength

Shape

ZURA

Sector

loading...

Top 5 RS in Group

Symbol

Company

RS

5-Day Perf.

Forecast

Shape
0

$0.70

Shape-309%

2025-EPS

0

Analyst rating

No Data Available

Last analyst upgrade/downgrade

H.C. Wainwright

initialise

Previous: Not converted

2024-09-05

Now: Neutral

Cantor Fitzgerald

initialise

Previous: Not converted

2024-06-12

Now: Overweight

Piper Sandler

initialise

Previous: Not converted

2024-05-03

Now: Overweight

BNP Paribas

initialise

Previous: Not converted

2023-10-10

Now: Overweight

Earnings GrowthShape

status-upYoY

Current

Estimates

Q2.22

arrow
arrow

N/A

-0.05
vs NA

Q3.22

arrow
arrow

N/A

-0.06
vs NA

Q1.23

arrow
arrow

N/A

-2.70
vs NA

Q2.23

arrow
arrow

N/A

-1.31
vs -0.05

Q3.23

arrow
arrow

N/A

-0.18
vs -0.06

Q4.23

arrow
arrow

N/A

-0.19
vs NA

Q1.24

arrow
arrow

N/A

-0.02
vs -2.70

Q2.24

arrow
arrow

N/A

-0.17
vs -1.31

Q3.24

arrow
arrow

N/A

-0.13
vs -0.18

Q4.24

arrow
arrow

N/A

-0.15
vs -0.19

Sales GrowthShape

status-upYoY

Current

Estimates

Q2.22

arrow
arrow

NA

NA  vs NA

Q3.22

arrow
arrow

NA

NA  vs NA

Q1.23

arrow
arrow

NA

NA  vs NA

Q2.23

arrow
arrow

NA

NA  vs NA

Q3.23

arrow
arrow

NA

NA  vs NA

Q4.23

arrow
arrow

NA

NA  vs NA

Q1.24

arrow
arrow

NA

NA  vs NA

Q2.24

arrow
arrow

NA

NA  vs NA

Return on EquityShape

status-upQoQ

Q3.22

arrow
arrow

-37%

-0.37
vs -0.23

Q4.22

arrow
arrow

NA

NA
vs -0.37

Q1.23

arrow
arrow

-34%

-0.34
vs NA

Q2.23

arrow
arrow

-49%

-0.49
vs -0.34

Q3.23

arrow
arrow

-13%

-0.13
vs -0.49

Q4.23

arrow
arrow

-14%

-0.14
vs -0.13

Q1.24

arrow
arrow

-1%

-0.01
vs -0.14

Q2.24

arrow
arrow

-8%

-0.08
vs -0.01

Institutionnal OwnershipShape

status-up

Earnings Growth

Latest News

ZURA

businesswire.com

6 hours ago

CPS HR Consulting Partners with GovInvest to Revolutionize Compensation Consulting with Advanced Technology
ZURA

investorplace.com

6 hours ago

3 Undervalued Biotech Stocks With Breakout Potential
ZURA

investorplace.com

6 hours ago

The 3 Most Undervalued Biotech Stocks to Buy in July 2024
ZURA

businesswire.com

6 hours ago

Zura Bio Presents Data for the Tibulizumab (ZB-106) Program at EULAR 2024
ZURA

businesswire.com

6 hours ago

Zura Bio Forms Scientific Advisory Board with Prominent Specialists in Rheumatology, Dermatology, and Immunology
ZURA

businesswire.com

6 hours ago

Zura Bio to Present Data Exploring the Expanded Potential of Tibulizumab (ZB-106) into Sjogren's Syndrome and Rheumatoid Arthritis at EULAR 2024

New Feature Coming Soon, Stay Tuned!

ShapeShape